Elderly patients with hair loss are at higher risk of developing androgenic alopecia and may therefore benefit from preventive or long-term treatment with oral finasteride. However, the optimal dosage of oral finasteride, based on age, clinical efficacy, and patient-specific factors, is still uncertain. Therefore, the present study was conducted to assess the efficacy of finasteride as a hair loss treatment in a cohort of elderly men with male pattern hair loss.
A total of 515 men, aged 40–60 years, with male pattern hair loss in a period of 3 years or more were included in the present study. The mean age was 54.4 ± 5.6 years. The patients were divided into two groups according to the type of hair loss (hair loss type A, B or C). All the patients had mild to moderate alopecia. All the patients were instructed to stop the medication after 3 months of treatment. All patients had to use a daily oral dose of 1 mg/day of finasteride. The treatment period was defined by at least 1 year.
The participants were divided into two groups based on the type of hair loss (hair loss type A or B) and the dose of finasteride. In group A, the finasteride dose was 1 mg/day, whereas in group B, the finasteride dose was 3 mg/day (see Fig. ).
Fig. 1The effect of finasteride in the treatment of male pattern hair loss with and without alopecia. A total of 515 men were included in the study, and the mean age was 54.4 ± 5.6 years.
All the patients were randomized to receive finasteride or placebo for 1 month at the start of the study and then again after 3 months. The study protocol was approved by the Ethics Committee of the Medical College, Qingcheng Hospital, Qingcheng University, Qingcheng, China.
The mean age of the study group was 66.1 ± 5.5 years, and the mean age in group A was 62.7 ± 5.3 years. The mean duration of hair loss was 3.5 ± 0.9 years. The median hair loss in group B was 6.1 ± 1.2 hairs. There was no significant difference between the two groups in hair loss duration (p = 0.08).
In group B, the mean hair loss was 3.6 ± 0.4 hairs in group A, 4.0 ± 0.3 hairs in group B, and 3.2 ± 0.2 hairs in group C (p = 0.08). There was a significant difference between the two groups in the percentage of patients experiencing the first hair loss (p = 0.003).
The mean age of the study group was 61.2 ± 4.5 years, and the mean age of the study group in group B was 62.3 ± 5.5 years. The mean duration of hair loss in group A was 3.5 ± 0.9 years, and in group B was 5.1 ± 1.3 years. The median hair loss in group B was 2.1 hairs, and the median hair loss in group C was 0.8 hairs. The number of hairs in group B was significantly higher in the 1-mg group than in the 3-mg group (p = 0.03).
In group A, the mean hair loss was 3.8 ± 0.4 hairs in group B, 2.2 hairs in group B, and 2.6 hairs in group C (p = 0.03). In group B, the median hair loss was 5.4 hairs in the 1-mg group, 4.3 hairs in group B, and 4.6 hairs in group C (p = 0.04). There was a significant difference between the two groups in the percentage of patients experiencing the hair loss duration (p = 0.003).
There was no significant difference between the two groups in the percentage of patients experiencing the hair loss duration (p = 0.03).
Finasteride, a 5-alpha reductase inhibitor, was found to be effective in the treatment of male pattern hair loss in the present study. The finasteride dose was 1 mg/day in the study period, and the average dose of finasteride in the study period was 3 mg/day. The mean finasteride dose in group B was 3 mg/day.
Background:The use of topical finasteride and/or minoxidil for the treatment of benign prostatic hyperplasia (BPH) in men has become increasingly popular. However, the effects of topical finasteride on the cardiovascular system and the endocrine system in the treatment of BPH are not well studied. Here, we investigated the effect of topical finasteride, a nonsteroidal anti-inflammatory drug (NSAID), and minoxidil on serum TSH concentrations, TGF-β and HMG-CoA reductase activity in men with and without a history of prostate cancer. Patients with BPH and BPH associated with an organic cause were treated with topical finasteride and/or minoxidil. Blood was drawn after 4 hours, after 1 hour and 1 hour after 4 weeks of daily finasteride use. TSH concentrations were measured by high-performance liquid chromatography. The study also included patients with an organic cause who had a history of prostate cancer, BPH and a history of prostate surgery, and those who were treated with finasteride for 1 year or more. The study included patients with a history of prostate cancer, BPH and a history of prostate surgery who were treated with topical finasteride and/or minoxidil. The primary endpoints were changes in TSH concentrations during the first year after finasteride treatment (primary end point) and in the second year after finasteride treatment (secondary end point). The secondary end point was the change in TSH concentrations during the first year after finasteride treatment. The study included 488 men with a mean age of 59.4 years (95% confidence interval: 59.9 to 59.7 years), including 549 men with a history of prostate cancer (n = 547), and 637 men with a history of BPH (n = 547) or prostate cancer (n = 547). The results of the study showed that the use of topical finasteride and/or minoxidil, either alone or in combination with finasteride, was associated with an increase in TSH concentrations during the first year after the treatment of BPH (P < 0.05) and prostate cancer (P > 0.05) with a corresponding increase in the secondary end point (P > 0.05). In addition, the use of topical finasteride, or in combination with minoxidil, was associated with a decrease in the TSH concentration during the first year after finasteride treatment (P < 0.05) and an increase in the secondary end point (P > 0.05).
Conclusion:Topical finasteride and/or minoxidil were associated with an increase in TSH concentrations during the first year after the treatment of BPH and a decrease in the secondary end point (P < 0.05). The use of topical finasteride and/or minoxidil, either alone or in combination with finasteride, was associated with an increase in TSH concentrations during the first year after finasteride treatment (P > 0.05).
Finasteride for the treatment of benign prostatic hyperplasia and BPH (prostate cancer)However, the effects of topical finasteride and/or minoxidil on the cardiovascular system and the endocrine system in the treatment of BPH are not well studied. Here, we investigated the effects of topical finasteride, a nonsteroidal anti-inflammatory drug (NSAID), and/or minoxidil on serum TSH concentrations in men with and without a history of prostate cancer, BPH and prostate cancer. We also evaluated the effects of topical finasteride on the cardiovascular system and the endocrine system in men with a history of prostate cancer, BPH and a history of prostate surgery, and those treated with topical finasteride for 1 year or more. Finally, we investigated the effects of topical finasteride and/or minoxidil on the cardiovascular system and the endocrine system in men with and without a history of prostate cancer, BPH and prostate cancer. We also investigated the effects of topical finasteride and/or minoxidil on the cardiovascular system and the endocrine system in men with and without a history of prostate cancer, BPH and a history of prostate surgery, and those treated with topical finasteride for 1 year or more.
Citation:Piloveiro J, Lechara D, et al.
Propecia is a popular medication for treating hair loss in men, known medically as ‘finasteride’. It is a medication primarily used to treat male pattern baldness (androgenetic alopecia) and is marketed by the pharmaceutical company Propecia. It is available in various forms, including tablets, oral pills and injections.
Propecia works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to hair loss and male pattern baldness. DHT is a hormone that plays a key role in the development and maintenance of male and female patterned hair.
Propecia works by inhibiting the enzyme 5-alpha reductase, which converts testosterone to DHT. DHT is a hormone that plays a key role in the development of male and female patterned hair.
Propecia is effective at treating male pattern baldness and reducing hair loss. However, it comes with potential side effects and contraindications, which can affect its effectiveness and safety.
In addition to its use in treating male pattern baldness and reducing hair loss, Propecia is also used to treat benign prostatic hyperplasia (BPH), which is a condition characterized by enlarged prostate gland and urinary problems.
Take Finax 1mg Tablet as advised by your doctor. Swallow the medicine with a glass of water. Do not crush or chew the medicine.
Take one tablet daily, preferably at the same time each day. Follow your doctor's instructions and do not exceed the recommended dosage.
If you miss a dose of Finax 1mg, take it as soon as you remember. However, if it’s close to the time for your next dose, skip the missed one and continue with your regular schedule. Do not take a double dose to make up for the missed tablet. Consistent daily use is essential for optimal results in managing hair loss. Always consult your doctor for specific advice regarding missed doses.
Long-term use of Finax tablets may cause potential side effects, such as decreased libido, erectile dysfunction, or depression, may persist or appear over time.
Regular follow-ups with a doctor are essential to monitor your health and assess continued suitability.
Long-term benefits, like sustained hair regrowth and reduced hair loss, can be seen with consistent use, but stopping the medication may reverse results.
Studies suggest that prolonged use of finasteride may be associated with health risks, including non-alcoholic fatty liver disease (NAFLD), insulin resistance, type 2 diabetes mellitus (T2DM), dry eye disease, and potential kidney issues.
Finax (finasteride 1mg) is not typically recommended for women, particularly during pregnancy, as it can cause birth defects in male fetuses. It may be prescribed in some cases for women with severe hair loss (such as post-menopausal women), but under strict medical supervision. Women are often advised to explore other treatments, like minoxidil, for hair regrowth. Always consult a healthcare provider before considering Finax for any use in women.
Read More About. (PHT, multipotocyment of type 2 diabetes).Finasteride, also known as male reducer, is a medication commonly prescribed for non-alcoholic fatty liver disease (NASH). It works by inhibiting the production of aspartate ampersorase and hydroxyzine, essential organ that cause muscle and hair growth.
Finax, also known as male reducer, is a drug mainly used to treat hair loss in men. It works by inhibiting the action of male hormone, dihydrotestosterone (DHT), essential for stopping the medication. DHT is a derivative of testosterone and causes hair follicles to shrink and bleed more easily. The purpose of Finax is to hinder the production of a hormone that will help hair to grow to cover with hair.
The dosage of Finax (1mg) of Finasteride (finasteride 0.3mg) is based on your medicine- your age, medical history, and response to other treatments.
Your doctor may change the dose of Finax (1mg) of Finasteride (finasteride 0.3mg) between your medicine and your doctor's advice. Consistent daily use for thrush is highly recommended.
Withdrawal times for any health condition may affect its symptoms. Symptoms may include scalp hair loss, loss of hair in your wake, day 5 of your past year, or hair loss in your late forties or late fifties. If you have severe or persistent symptoms, you may include difficulty in concentration, severe mood changes, new hairstearing, or bra capacity depression.
If you’re a new user of Propecia (finasteride) you’re not alone. It’s one of the most effective treatments for male pattern baldness. You should consider buying it from an online pharmacy. The medication works by stopping the conversion of testosterone into DHT, a hormone that is responsible for hair loss. By doing so, it reduces the rate of hair loss in areas where your hair loss has already been thined. This can help prevent further hair loss from occurring.
There are many online pharmacies that sell Propecia. They can supply a wide range of dosages, and it’s important to note that they may not be suitable for everyone. In addition, some people may prefer to take the medication with their doctor’s advice, while others prefer not to take the medication. It’s also important to note that some people prefer to buy Finasteride online, as it is less expensive. The best price for Finasteride is around £30, which is significantly cheaper than buying it from a local pharmacy. It’s worth noting that it’s possible to buy Propecia from an online pharmacy without a prescription. However, it’s important to be cautious about buying from unknown sources. Buying from an unregulated source can be risky, as the medication can be dangerous. It’s best to purchase the medication online from trusted sources, such as those that require a prescription. When buying from a trusted source, you’ll want to make sure you’re purchasing from a reputable and reliable pharmacy.
Stade de France Pharmacy